JNJ Earnings Prediction
The chart below shows how JNJ performed 10 days before and after its earnings report, based on data from the past quarters. Typically, JNJ sees a -0.01% change in stock price 10 days leading up to the earnings, and a +0.28% change 10 days following the report. On the earnings day itself, the stock moves by +0.15%. This data can give you a slight idea of what to expect for the next quarter's release.
JNJ Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
22.47B
5.25%
0.11%
Gross Margin
69.04%
-1.54%
-0.53%
Operating Margin
25.75%
-15.74%
-18.67%
Net Margin
11.99%
-40.58%
-42.58%
EPS
1.11
-89.13%
-42.49%
No Data Available
JNJ Earnings Analysis
Johnson & Johnson Corporation (JNJ.N) Earnings Conference Call
Positive
Q3 Sales Growth Analysis: Strong Q3 operational sales growth of 6.3%, with U.S. growth at 7.6% and international growth at 4.6%.
Innovative Medicine Sales Surge: Innovative Medicine sales exceeded $14 billion for the second consecutive quarter, with 11 key brands achieving double-digit growth.
DARZALEX Sales Surge: DARZALEX reached $3 billion in sales for the quarter, marking a 22.9% growth driven by market share gains.
MedTech Sales Surge: MedTech sales increased by 6.4%, with cardiovascular products showing double-digit growth, particularly from the Shockwave acquisition.
Free Cash Flow Increase: Free cash flow year-to-date was approximately $14 billion, up from $12 billion last year, indicating strong financial health.
Negative
Earnings Decline Analysis: Net earnings decreased to $2,700,000,000 with diluted earnings per share dropping to $1.11, down from $1.69 a year ago, reflecting a significant decline in profitability.
Earnings Performance Decline: Adjusted net earnings fell by 13.3% to $5,900,000,000, and adjusted diluted earnings per share decreased by 9% to $2.42 compared to Q3 2023, indicating a downward trend in earnings performance.
Innovative Medicine Margin Decline: The Innovative Medicine segment's margin declined from 45.4% to 37.9%, primarily due to a $1,250,000,000 acquired IPR and D expense, negatively impacting overall profitability.
Talc Litigation Expense Impact: Other income and expense showed a net expense of $1,800,000,000, a significant increase from $500,000,000 in the prior year, largely driven by a $1,750,000,000 charge related to the talc litigation settlement proposal.
Rising Effective Tax Rate: The effective tax rate increased to 19.3% from 17.4% year-over-year, primarily due to the tax treatment of the NM26 bispecific antibody acquisition, indicating rising tax burdens affecting net income.
JNJ FAQs
How does JNJ typically perform around its earnings report dates?
Is Earnings call transcript: Johnson & Johnson Q3 2024 beats EPS forecast positive or negative?
How can historical earnings data help predict future stock performance?
JNJ Earning Call Sentiment
Earnings call transcript: Johnson & Johnson Q3 2024 beats EPS forecast
JNJ.N
4.13%Positive
The earnings call reveals mixed signals: robust sales growth in key products and positive MedTech developments are offset by a decline in margins and increased litigation expenses. The Q&A session highlights confidence in future MedTech performance and strategic product replacements for XELARA losses, but concerns remain about the talc litigation and challenges in Asia. The positive sales guidance and strong cash position are balanced by earnings declines and margin pressures, suggesting a neutral market reaction.